Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2019-05-08 AGM Information
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled 'Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)' and details resolutions passed at the meeting held on May 8, 2019. Key topics covered include the adoption of financial statements, election of board members and auditors, approval of remuneration, and adoption of incentive programs and authorizations. These are the core activities and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document is a summary/bulletin of the meeting's outcomes, not a proxy statement (PSI) or a full annual report (10-K).
2019-05-08 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Calliditas Therapeutics AB covering the period 1 January – 31 March 2019. It contains financial highlights (net sales, profit/loss, earnings per share, cash position), management commentary (VD-ord), and detailed operational updates on clinical trials (NefIgArd study). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2019
2019-05-08 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January 1 – March 31, 2019' for Calliditas Therapeutics AB. It contains key financial figures (net sales, net income, earnings per share, cash equivalents), a CEO statement, business overview, and detailed information regarding clinical trials. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2019
2019-05-08 English
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of annual general meeting of Calliditas Therapeutics AB (publ)". It details the date, time, location, registration procedures, proposed agenda items (including election of directors, approval of financial statements, and remuneration guidelines), and specific proposals related to board composition and incentive programs. This content is characteristic of the official notice sent to shareholders summoning them to the Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2019-04-04 English
Annual Report 2018
Annual Report Classification · 100% confidence The document is an 'Årsredovisning' (Annual Report) for Calliditas Therapeutics AB for the year 2018. It contains a comprehensive overview of the company, including the Board of Directors' report (Förvaltningsberättelse), financial statements (Resultaträkning, Balansräkning, Kassaflödesanalys), accounting principles, notes, and an audit report (Revisionsberättelse). It covers the full fiscal year and provides substantive financial data, fitting the definition of an Annual Report (10-K). FY 2018
2019-04-04 Swedish
Annual Report 2018
Annual Report Classification · 100% confidence The document is a comprehensive annual report for Calliditas Therapeutics for the fiscal year 2018. It contains a table of contents, CEO statement, business highlights, detailed financial statements (income statement, balance sheet, cash flows), accounting policies, and an auditor's report. It is clearly the full annual report, not an announcement or summary. FY 2018
2019-04-04 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.